Corporate Information And Statement Of Ifrs Compliance [Abstract]
| Concept |
As at 2020-12-31 |
2020-01-01 to 2020-12-31 |
As at 2019-12-31 |
2019-01-01 to 2019-12-31 |
|---|---|---|---|---|
| Corporate information and statement of IFRS compliance [abstract] | ||||
| Name of reporting entity or other means of identification | — |
Novozymes A/S
|
— | — |
| Domicile of entity | — |
Denmark
|
— | — |
| Legal form of entity | — |
Stock-based corporation
|
— | — |
| Country of incorporation | — |
Denmark
|
— | — |
| Address of entity's registered office | — |
Krogshoejvej 36, 2880 Bagsvaerd
|
— | — |
| Principal place of business | — |
Denmark
|
— | — |
| Description of nature of entity's operations and principal activities | — |
The objects of the company are to carry out research in, development and production of and trade in biological solutions, including enzymes, microorganisms and other biotechnological processes and products as well as any other related activities as may be specified by the Board of Directors. The company strives to operate in a sustainable and responsible manner, inter alia in a financial, environmental and social regard.
|
— | — |
| Name of parent entity | — |
Novo Holdings A/S
|
— | — |
| Name of ultimate parent of group | — |
Novo Nordisk Foundation
|
— | — |
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [text block] | — | — | — | — |
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [abstract] | ||||
| Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items] | ||||
| Current inventories |
2,361,000,000
DKK
|
— |
2,613,000,000
DKK
|
— |
| Current trade receivables |
2,549,000,000
DKK
|
— |
2,864,000,000
DKK
|
— |
| Current trade payables |
1,100,000,000
DKK
|
— |
1,117,000,000
DKK
|
— |
| Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners per share | — |
5.25
|
— |
5.25
|